Zobrazeno 1 - 10
of 393
pro vyhledávání: '"Ed Schuuring"'
Autor:
Kelly M. Castañeda, Grigory Sidorenkov, Marian J. E. Mourits, Bert van der Vegt, Albert G. Siebers, Karin M. Vermeulen, Ed Schuuring, G. Bea A. Wisman, Geertruida H. de Bock
Publikováno v:
BMC Public Health, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Regular participation in cervical cancer screening is critical to reducing mortality. Although certain sociodemographic factors are known to be associated with one-time participation in screening, little is known about other facto
Externí odkaz:
https://doaj.org/article/d91a503852f942ab8180ba63eb3be867
Autor:
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N.M. Dinjens, Jurgen Fütterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W.J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G.L. Vanneste, Erik Vegt, André N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 23-31 (2023)
Background: Germline and tumour genetic testing in prostate cancer (PCa) is becoming more broadly accepted, but testing indications and clinical consequences for carriers in each disease stage are not yet well defined. Objective: To determine the con
Externí odkaz:
https://doaj.org/article/6f52ae4fdd99475585e6ab93b18449bb
Autor:
Kelly Dufraing, Kaat Van Casteren, Joke Breyne, Nicky D’Haene, Claude Van Campenhout, Sara Vander Borght, Karen Zwaenepoel, Etienne Rouleau, Ed Schuuring, Jan von der Thüsen, Elisabeth Dequeker
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-20 (2022)
Abstract Background For patients with non-small cell lung cancer (NSCLC), targeted therapies are becoming part of the standard treatment. It is of question which information the clinicians provide on test requests and how the laboratories adapt test
Externí odkaz:
https://doaj.org/article/005a0612409243a0b303ce9ae8fd9332
Autor:
Jennifer A. Fairley, Melanie H. Cheetham, Simon J. Patton, Etienne Rouleau, Marc Denis, Elisabeth M. C. Dequeker, Ed Schuuring, Kaat van Casteren, Francesca Fenizia, Nicola Normanno, Zandra C. Deans
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Circulating cell free DNA (cfDNA) testing of plasma for EGFR somatic variants in lung cancer patients is being widely implemented and with any new service, external quality assessment (EQA) is required to ensure patient safety. An
Externí odkaz:
https://doaj.org/article/2db9d6d558434af387830fabde90da75
Autor:
Kelly M. Castañeda, Grigory A. Sidorenkov, Jolien de Waard, Marcel J.W. Greuter, Bert van der Vegt, Inge M.C.M. de Kok, Albert G. Siebers, Karin M. Vermeulen, G. Bea A. Wisman, Ed Schuuring, Geertruida H. de Bock
Publikováno v:
Preventive Medicine Reports, Vol 32, Iss , Pp 102166- (2023)
Research has long since confirmed the benefits of regular cervical cancer screening (CCS) worldwide. However, some developed countries have low participation rates despite well-organized screening programs. Given that studies in Europe typically defi
Externí odkaz:
https://doaj.org/article/2cf42f39a70f4a7ba5db6fa9071c0e04
Autor:
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed when alectinib minimum plasma con
Externí odkaz:
https://doaj.org/article/4457ff0cdd7b4bd9aa0922759784c7a7
Autor:
Paul van der Leest, Melanie Janning, Naomi Rifaela, Maria L. Aguirre Azpurua, Jolanthe Kropidlowski, Sonja Loges, Nicolas Lozano, Alexander Sartori, Darryl Irwin, Pierre-Jean Lamy, T. Jeroen N. Hiltermann, Harry J. M. Groen, Klaus Pantel, Léon C. van Kempen, Harriet Wikman, Ed Schuuring
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 17, p 13390 (2023)
Analysis of circulating tumor DNA (ctDNA) is a potential minimally invasive molecular tool to guide treatment decision-making and disease monitoring. A suitable diagnostic-grade platform is required for the detection of tumor-specific mutations with
Externí odkaz:
https://doaj.org/article/c936b2488010400d999d66cac61da295
Autor:
Paul van derLeest, Birgitta Hiddinga, Anneke Miedema, Maria L. Aguirre Azpurua, Naomi Rifaela, Arja terElst, Wim Timens, Harry J. M. Groen, Léon C. vanKempen, T. Jeroen N. Hiltermann, Ed Schuuring
Publikováno v:
Molecular Oncology, Vol 15, Iss 11, Pp 2910-2922 (2021)
Immunotherapy for metastasized non‐small‐cell lung cancer (NSCLC) can show long‐lasting clinical responses. Selection of patients based on programmed death‐ligand 1 (PD‐L1) expression shows limited predictive value for durable clinical bene
Externí odkaz:
https://doaj.org/article/3d6ef98ec808424e9bf8c4b94e7a4fc2
Autor:
Martine Froukje van der Kamp, Eric Hiddingh, Julius de Vries, Boukje Annemarie Cornelia van Dijk, Ed Schuuring, Lorian Slagter-Menkema, Bert van der Vegt, Gyorgy Bela Halmos
Publikováno v:
Cancers, Vol 15, Iss 15, p 3834 (2023)
There is often a mismatch between the chronological and biological age of head and neck squamous cell carcinoma (HNSCC) patients. Treatment is based on chronological age, while biological age seems to be a better prognosticator for treatment tolerati
Externí odkaz:
https://doaj.org/article/bb4ab5d64f28477d80e804b29601f928
Autor:
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy. In this randomised controlled trial we investigated whether i
Externí odkaz:
https://doaj.org/article/7a4d1f9500d043fca5a9dd6a08afeeba